|1.||Le Pen, Gwenaëlle: 5 articles (06/2011 - 06/2006)|
|2.||Krebs, Marie-Odile: 5 articles (06/2011 - 06/2006)|
|3.||Jay, Thérèse M: 3 articles (06/2011 - 05/2009)|
|4.||Maćkowiak, Marzena: 2 articles (12/2015 - 02/2014)|
|5.||Latusz, Joachim: 2 articles (12/2015 - 02/2014)|
|6.||Bator, Ewelina: 2 articles (12/2015 - 02/2014)|
|7.||Wędzony, Krzysztof: 2 articles (12/2015 - 02/2014)|
|8.||Finardi, Adele: 2 articles (01/2014 - 09/2013)|
|9.||Colciaghi, Francesca: 2 articles (01/2014 - 09/2013)|
|10.||Nobili, Paola: 2 articles (01/2014 - 09/2013)|
05/01/1982 - "Methylazoxymethanol is a potent carcinogen and induces tumors predominantly of the small intestine and colon following a single injection. "
01/01/1981 - "Methylazoxymethanol (MAM) is a potent carcinogen and induces tumors predominantly in rat liver, colon and kidney. "
01/01/1990 - "Experiment 1: The numbers of hyperplastic liver cell foci and the incidence of colon tumors in male and female Syrian golden hamsters given a single intravenous injection of methylazoxymethanol (MAM) acetate and then fed the diet containing 0.025% CA for 24 wk were significantly lower than those of hamsters given MAM acetate alone. "
02/26/1997 - "Because the incidence of colonic tumors induced by methylazoxymethanol (MAM) in rats was shown to be enhanced by X-irradiation, we immunohistochemically analyzed these colonic carcinomas for the presence of p53 gene mutations. "
09/01/1998 - "The aim of this study was to determine whether the cytosolic enzyme alcohol dehydrogenase (ADH) activates methylazoxymethanol (MAM) in the mouse colon and whether differential tumor susceptibility in the mouse is dependent, in part, on strain-related differences in MAM metabolism by ADH. "
|2.||Schizophrenia (Dementia Praecox)
11/01/2015 - "Gestational day 17 methylazoxymethanol (MAM) treatment has been shown to reproduce, in rodents, some of the alterations in cortical and mesolimbic circuitries thought to contribute to schizophrenia. "
06/01/2011 - "Exposure to methylazoxymethanol (MAM) at embryonic day 17 (E17) in the rat has been proposed to be a promising model for schizophrenia that mimics behavioural abnormalities and deficits in prefrontal cortex (PFC) networks. "
01/01/2010 - "Adult rats exposed to methylazoxymethanol (MAM) at embryonic day 17 (E17) consistently display behavioral characteristics similar to that observed in patients with schizophrenia and replicate neuropathological findings from the prefrontal cortex of psychotic individuals. "
06/01/2007 - "Prenatal methylazoxymethanol (MAM) administration at gestational day 17 has been shown to induce in adult rats schizophrenia-like behaviours as well as morphological and/or functional abnormalities in structures such as the hippocampus, medial prefrontal cortex (mPFC) and nucleus accumbens (NAcc), consistent with human data. "
03/01/2007 - "A rat model of altered prenatal brain development resembling the onset of schizophrenia has been obtained by administering in fetus methylazoxymethanol (MAM) at gestational day 12 which impairs the growth of limbic pathways between the entorhinal cortex and the hippocampus. "
|3.||Body Weight (Weight, Body)
03/01/2007 - "Methylazoxymethanol (15 mg/kg body weight, day 43) was examined for comparison and caused similar hypoplasia of the guinea pig cerebellum, but did also induce a reduction in body weight. "
01/01/1997 - "Intraperitoneal administration of methylazoxymethanol (MAM) acetate (0.05 microl/g of body weight) in male Sprague-Dawley rats aged 3 days produced cell death in the external granule layer of the cerebellum which peaked at 48 hours (h) and was followed by removal of cellular debris at 72 h. "
12/01/1986 - "Weanling male Sprague-Dawley rats were injected via the tail vein with methylazoxymethanol (MAM) acetate at a dose of 70 mg/kg body weight. "
04/01/1986 - "Methylazoxymethanol (MAM) acetate, at a weekly dose of 0.2 mg/10 g body weight, was given to germfree mice and to mice monocontaminated with either L. "
11/01/1985 - "Both groups were orally administered 0.3 mg/10 g of body weight (B.W.) of methylazoxymethanol (MAM) acetate. "
01/26/1998 - "Injection of the antimitotic drug methylazoxymethanol (MAM) in the pregnant rat at E14 leads in the offsprings to a severe malformation with microcephaly and cortical heterotopiae in the white matter and in the CA1 field of the hippocampus. "
02/01/1984 - "Methylazoxymethanol (MAM), an alkylating agent which kills dividing cells, produces microcephaly when administered to rats at 15 days gestation. "
09/01/1974 - "[Proceedings: Changes in cerebral amine content in experimental microcephaly in rats induced by methylazoxymethanol administration and their behavior changes]."
03/01/1990 - "Methylazoxymethanol-lesioned animals with mild cortical hypoplasia remained measurably hyperactive and may serve as a model for the study of neurotransmitter and neuropathologic abnormalities associated with hyperactivity in children with microcephaly."
01/01/1998 - "Abnormal development of serotonin nerve fibers in the visual cortex in rats with methylazoxymethanol-induced microcephaly."
|5.||Malformations of Cortical Development
03/01/2008 - "Our lab studies a model of cortical dysplasia induced by injection of methylazoxymethanol (MAM) into pregnant ferrets on embryonic day 33 (E33), which shares many features of neocortical dysplasia in humans. "
09/01/2013 - "To investigate cellular and molecular bases of epileptogenic mechanisms and possible effect of severe epilepsy on the malformed cortex we have here performed a parallel analysis of a rat model of acquired cortical dysplasia previously established in our laboratory, i.e., the methylazoxymethanol/pilocarpine (MAM-PILO) rats, and surgical samples from patients with type IIB FCD. "
01/01/2014 - "We previously demonstrated in a rat model of acquired focal cortical dysplasia, the methylazoxymethanol/pilocarpine - MAM/pilocarpine - rats, that the occurrence of status epilepticus (SE) and subsequent seizures fostered a pathologic process capable of modifying the morphology of cortical pyramidal neurons and NMDA receptor expression/localization. "
|1.||2-Acetylaminofluorene (2 Acetylaminofluorene)
|9.||Neurotransmitter Agents (Neurotransmitter)
|10.||Growth Hormone-Releasing Hormone (Somatotropin Releasing Hormone)